A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

Vaccine

Volumn 28, Issue 2, 2009, Pages 512-522

  Schabowsky, Rich Henry ^a   Elpek, Kutlu G ^a   Madireddi, Shravan ^a   Sharma, Rajesh K ^a   Yolcu, Esma S ^a   Bandura Morgan, Laura ^a   Miller, Robert ^b   MacLeod, Kathryn J ^b   Mittler, Robert S ^c   Shirwan, Haval ^a  

^a Department of Microbiology and Immunology   (United States)

^b ApoImmune Inc   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 1BB; Adjuvant; Costimulation; SA 4 1BBL; Toxicity; Vaccines

Indexed keywords

CD137 LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS; HYPOTHESIS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLENOMEGALY; T LYMPHOCYTE; TOXICITY;

4-1BB LIGAND; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS, CD137; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; T-LYMPHOCYTES;

EID: 70649103798     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.127     Document Type: Article

References (49)

1. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005) 23-68
2. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12 (2006) 693-698
3. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109 (2002) 651-659
4. Halstead E.S., Mueller Y.M., Altman J.D., and Katsikis P.D. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 3 (2002) 536-541
5. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3 (1997) 682-685
6. Hixon J.A., Blazar B.R., Anver M.R., Wiltrout R.H., and Murphy W.J. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 7 (2001) 136-143
7. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 178 (2007) 4194-4213
8. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028
9. Ferlin W.G., von der W.T., Cottrez F., Ferrick D.A., Coffman R.L., and Howard M.C. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur J Immunol 28 (1998) 525-531
10. Hixon J.A., Anver M.R., Blazar B.R., Panoskaltsis-Mortari A., Wiltrout R.H., and Murphy W.J. Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol Blood Marrow Transplant 8 (2002) 316-325
11. van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99 (2002) 5561-5566
12. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25 (2007) 876-883
13. Kwon B.S., and Weissman S.M. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86 (1989) 1963-1967
14. Pollok K.E., Kim Y.J., Zhou Z., Hurtado J., Kim K.K., Pickard R.T., et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 150 (1993) 771-781
15. Bukczynski J., Wen T., Ellefsen K., Gauldie J., and Watts T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci USA 101 (2004) 1291-1296
16. Myers L., Lee S.W., Rossi R.J., Lefrancois L., Kwon B.S., Mittler R.S., et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol 18 (2006) 325-333
17. Takahashi C., Mittler R.S., and Vella A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 162 (1999) 5037-5040
18. Waller E.C., McKinney N., Hicks R., Carmichael A.J., Sissons J.G., and Willis M.R. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 110 (2007) 4360-4366
19. Miller R.E., Jones J., Le T., Whitmore J., Boiani N., Gliniak B., et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 169 (2002) 1792-1800
20. Rabu C., Quemener A., Jacques Y., Echasserieau K., Vusio P., and Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 280 (2005) 41472-41481
21. Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A., Goldstein M.D., et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 187 (1998) 1849-1862
22. Elpek K.G., Yolcu E.S., Franke D.D., Lacelle C., Schabowsky R.H., and Shirwan H. Ex vivo expansion of CD4 + CD25 + FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 179 (2007) 7295-7304
23. Sharma R.K., Elpek K.G., Yolcu E.S., Schabowsky R.H., Zhao H., Bandura-Morgan L., and Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 69 (2009) 4319-4326
24. Fukushima A., Yamaguchi T., Ishida W., Fuckata K., Mittler R.S., Yagita H., et al. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 175 (2005) 4897-4903
25. Irie J., Wu Y., Kachapati K., Mittler R.S., and Ridgway W.M. Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 56 (2007) 186-196
26. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186 (1997) 47-55
27. Robertson S.J., Messer R.J., Carmody A.B., Mittler R.S., Burlak C., and Hasenkrug K.J. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol 180 (2008) 5267-5274
28. Wang J., Guo Z., Dong Y., Kim O., Hart J., Adams A., et al. Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant 3 (2003) 543-551
29. Chang J.T., Palanivel V.R., Kinjyo I., Schambach F., Intlekofer A.M., Banerjee A., et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007) 1687-1691
30. Harrington L.E., Galvan M., Baum L.G., Altman J.D., and Ahmed R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med 191 (2000) 1241-1246
31. Manjunath N., Shankar P., Wan J., Weninger W., Crowley M.A., Hieshima K., et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 108 (2001) 871-878
32. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179 (2007) 3325-3331
33. Takai T., Li M., Sylvestre D., Clynes R., and Ravetch J.V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994) 519-529
34. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 24 (2006) 19-28
35. Wilcox R.A., Chapoval A.I., Gorski K.S., Otsuji M., Shin T., Flies D.B., et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 168 (2002) 4262-4267
36. Futagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H., et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14 (2002) 275-286
37. Zhu G., Flies D.B., Tamada K., Sun Y., Rodriguez M., Fu Y.X., et al. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice. J Immunol 167 (2001) 2671-2676
38. Zhu Y., Zhu G., Luo L., Flies A.S., and Chen L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109 (2007) 4882-4889
39. Jiang D., Chen Y., and Schwarz H. CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 181 (2008) 3923-3932
40. Langstein J., Michel J., Fritsche J., Kreutz M., Andreeesen R., and Schwarz H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 160 (1998) 2488-2494
41. Lippert U., Zachmann K., Ferrari D.M., Schwarz H., Brunner E., Latif M.-U.I., et al. CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 38 (2008) 1024-1032
42. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 77 (2005) 281-286
43. Sester U., Wabnitz G.H., Kirchgessner H., and Samstag Y. Ras/PI3kinase/cofilin-independent activation of human CD45RA+ and CD45RO+ T cells by superagonistic CD28 stimulation. Eur J Immunol 37 (2007) 2881-2891
44. Waibler Z., Sender L.Y., Merten C., Hartig R., Kliche S., Gunzer M., et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 3 (2008) e1708
45. Singh M., Basu S., Camell C., Couturier J., Nudelman R.J., Medina M.A., et al. Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells. Eur J Immunol 38 (2008) 1522-1532
46. Dennehy K.M., Elias F., Na S.Y., Fischer K.D., Hunig T., and Luhder F. Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 178 (2007) 1363-1371
47. Muller N., van den B.J., Odoardi F., Tischner D., Herath J., Flugel A., et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 118 (2008) 1405-1416
48. Gogishvili T., Langenhorst D., Luhder F., Elias F., Elfein K., Dennehy K.M., et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4 (2009) e4643
49. Choi B.K., Bae J.S., Choi E.M., Kang W.J., Sakaguchi S., Vinay D.S., et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4 + CD25+ T cells. J Leukoc Biol 75 (2004) 785-791